[ad_1]
The two companies said that the phase III trial data showed that the effective rate of the enhanced COVID-19 vaccine against this disease was 95.6%.
US pharmaceutical company Pfizer and its partner BioNTech stated that data from the Phase III trial showed that their booster dose of COVID-19 vaccine is highly effective against coronaviruses (including Delta variants).
They said that during the period of the Delta strain, trials with 10,000 participants 16 years of age or older showed that the disease was 95.6% effective.
The study also found that enhanced injection has good safety.
Pfizer once stated that the effectiveness of its two injections of the vaccine would decline over time, and cited a study that showed that its effectiveness reached a peak of 96% and 84% four months after the second injection. . Some countries have begun to implement enhanced dose plans.
The drug maker stated that the median time between the second dose in the study and the booster injection or placebo was about 11 months, adding that there were only 5 cases of COVID-19 in the booster injection group and 109 cases in the injection group . Placebo injection.
Pfizer CEO Albert Bourla said in a statement: “These results further demonstrate the benefits of boosters, because our goal is to keep people well protected against this disease.”
The median age of the participants was 53 years old, 55.5% of the participants were between 16 and 55 years old, and 23.3% of the participants were 65 years old or older.
The two companies said they will submit the detailed results of the trial to the U.S. Food and Drug Administration (FDA), the European Medicines Agency and other regulatory agencies as soon as possible for peer review and publication.
U.S. and European regulatory agencies have authorized Pfizer BioNTech and Moderna Inc to provide a third dose of COVID-19 vaccine to patients with compromised immune systems. These patients may be less protective of the two-dose regimen.
[ad_2]
Source link